









Markets
/
Stocks
/
nasdaq-stok
/

Stoke Therapeutics Inc

STOK

32.400USD

+1.920+6.30%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.79BMarket Cap

45.65P/E TTM



Stoke Therapeutics Inc

32.400

+1.920+6.30%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Stoke Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Stoke Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 26 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.44.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Stoke Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

26 / 392

Overall Ranking

121 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Stoke Therapeutics Inc Highlights

StrengthsRisks

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 194.68% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.55M.

Overvalued

The company’s latest PE is 45.65, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 69.94M shares, decreasing 5.77% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 184.75K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

38.444

Target Price

+26.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Stoke Therapeutics Inc is 7.39, ranking 115 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 10.63M, representing a year-over-year increase of 117.25%, while its net profit experienced a year-over-year increase of 45.09%.

Score

Industry at a Glance

Previous score

7.39

Change



Financials

9.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.59

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.40

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Stoke Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Stoke Therapeutics Inc is 5.39, ranking 379 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 45.65, which is 8.70% below the recent high of 49.62 and 116.94% above the recent low of -7.73.

Score

Industry at a Glance

Previous score

5.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Stoke Therapeutics Inc is 8.80, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 39.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

35.750

Target Price

+11.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Stoke Therapeutics Inc

STOK

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Stoke Therapeutics Inc is 9.36, ranking 13 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 36.18 and the support level at 26.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.95

Change

0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.534

Neutral

RSI(14)

54.759

Neutral

STOCH(KDJ)(9,3,3)

55.876

Neutral

ATR(14)

2.082

High Vlolatility

CCI(14)

113.373

Buy

Williams %R

27.748

Buy

TRIX(12,20)

-0.085

Sell

StochRSI(14)

47.694

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

31.888

Buy

MA10

30.901

Buy

MA20

30.427

Buy

MA50

31.449

Buy

MA100

29.560

Buy

MA200

21.400

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Stoke Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 122.44%, representing a quarter-over-quarter increase of 6.06%. The largest institutional shareholder is The Vanguard, holding a total of 3.14M shares, representing 5.50% of shares outstanding, with 8.05% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.93M

-0.40%

Lynx1 Capital Advisors LLC

5.40M

RTW Investments L.P.

5.12M

Baker Bros. Advisors LP

4.63M

Redmile Group, LLC

4.18M

-4.58%

Morgan Stanley & Co. LLC

3.48M

+3.02%

BlackRock Institutional Trust Company, N.A.

3.30M

+10.83%

TD Securities, Inc.

3.17M

The Vanguard Group, Inc.

Star Investors

3.15M

+7.30%

Skorpios Trust

2.26M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Stoke Therapeutics Inc is 4.22, ranking 98 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.